Radiopharmaceuticals company Navidea Biopharmaceuticals (NYSE Amex:NAVB) announced that the PDUFA date for its cancer diagnostics drug Lymphoseek has been pushed back three months to Sept. 10. The reason Dublin, Ohio-based Navidea gave for the U.S. Food and Drug Administration’s request was that the agency sought more data related to chemistry and manufacturing, according to a […]
Cardinal Health (NYSE:CAH) will set the price for Navidea Biopharmaceuticals‘ (NYSE Amex:NAVB) cancer drug that could be approved as soon as this summer. While Navidea, developed the drug, called Lymphoseek, Cardinal will distribute it and collect half of its sales in the U.S., Navidea has said. “In the final analysis, Cardinal will set the pricing,” […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Radiopharmaceuticals company Navidea Biopharmaceuticals (NYSE Amex:NAVB) has opened a Boston-area commercialization office. Employees at Navidea’s new Andover, Massachusetts office will focus much of their attention on the expected launch later this year of drug candidate Lymphoseek, a targeting agent used by surgeons to identify lymph nodes in patients with breast cancer or melanoma and to […]
A public ethics group is calling on the U.S. Securities and Exchange Commission to investigate a hedge fund manager who made headlines last year for being an outspoken short seller of Navidea Bioscience‘s (NASDAQ:NAVB) stock. Citizens for Responsibility and Ethics in Washington (CREW) said it’s looking into whether investors such as Martin Shkreli of MSMB […]
Radiopharmaceuticals developer Navidea Biopharmaceuticals (NYSE Amex:NAVB) has signed a deal that gives it the option to license a Parkinson’s disease imaging agent from Alseres Pharmaceuticals. Under the terms of the deal, Navidea (formerly known as Neoprobe) pays Alseres $500,000 for exclusive rights during a six-month period when it can perform due diligence and negotiate a […]
Radiopharmaceuticals developer Navidea Biopharmaceuticals (NYSE Amex:NAVB) has secured up to $10 million in debt financing that strengthens the company’s balance sheet and could help with future acquisitions or licensing deals. The debt funding comes from Hercules Technology Growth Capital (Nasdaq:HTGC), a financial firm that provides loans to technology companies, according to a statement from Dublin, […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.